TV-Enabled Antibody Platform Candidates
Neurodegenerative Diseases (e.g., targeting alpha-synuclein, tau)
Preclinical/DiscoveryResearch
Key Facts
Indication
Neurodegenerative Diseases (e.g., targeting alpha-synuclein, tau)
Phase
Preclinical/Discovery
Status
Research
Company
About Denali Therapeutics
Denali Therapeutics is a public biotech company focused on discovering, developing, and delivering medicines for serious diseases, with a particular emphasis on crossing biological barriers to reach the brain. The company's proprietary TransportVehicle™ platform is central to its strategy, aiming to transform treatment for neurodegenerative and lysosomal storage disorders. Denali has built a diverse clinical-stage pipeline through both internal R&D and strategic partnerships, positioning itself at the forefront of next-generation CNS therapeutics. The company is headquartered in South San Francisco, California, and trades on the NASDAQ under the ticker DNLI.
View full company profile